Abstract 971P
Background
The growing demand for hepatic resection in elderly hepatocellular carcinoma (HCC) patients highlights the need to understand the impact of preoperative frailty on surgical outcomes. This multicenter retrospective cohort study aimed to investigate the association between frailty and short-term and long-term outcomes following hepatic resection in elderly HCC patients.
Methods
We conducted a multicenter retrospective cohort study on elderly patients (≥70 years) who underwent curative-intent hepatic resection for HCC at 10 Chinese hospitals in China from 2012 to 2021. Frailty was assessed using the Clinical Frailty Scale (CFS), with frailty defined as CFS ≥ 5. Primary outcomes included overall survival (OS) and recurrence-free survival (RFS); secondary outcomes encompassed postoperative 30-day morbidity, 30-day mortality, and 90-day mortality. We compared these outcomes between patients with and without preoperative frailty.
Results
Of the 488 elderly patients, 148 (30.3%) were considered frail. Frail patients experienced significantly higher postoperative 30-day morbidity (68.9% vs. 43.2%), 30-day mortality (4.1% vs. 0.6%), and 90-day mortality (6.1% vs. 0.9%) than non-frail patients (all P<0.05). During a median follow-up of 37.7 months (IQR: 20.4-57.8), frail patients demonstrated significantly worse median OS (41.6 months [95% CI, 32.0-51.2] vs. 69.7 months [95% CI, 55.6-83.8]) and RFS (27.6 months [95% CI, 23.1-32.1] vs. 42.7 months [95% CI, 34.6-50.8]) compared to non-frail patients (both P<0.01). Multivariate Cox-regression analysis revealed frailty as a significant predictor for OS (HR 1.61, 95% CI 1.22-2.13, P=0.001) and RFS (HR 1.32, 95% CI 1.03-1.70, P=0.028).
Conclusions
Frailty was significantly associated with adverse short-term and long-term outcomes in elderly HCC patients undergoing hepatic resection. Our findings suggest that frailty assessment should be incorporated into perioperative and postoperative prognosis evaluation, and particular attention should be given to frail elderly patients undergoing this procedure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China; Dawn Project Foundation of Shanghai; Shanghai Health Academic Leader Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18